Top

Published in:

01-06-2009 | Epidemiology

DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus

Authors: Maria A. Loizidou, Thalia Michael, Susan L. Neuhausen, Robert F. Newbold, Yiola Marcou, Eleni Kakouri, Maria Daniel, Panayiotis Papadopoulos, Simos Malas, Andreas Hadjisavvas, Kyriacos Kyriacou

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Abstract

The DNA repair pathway is known to play a role in the etiology of breast cancer. A number of studies have demonstrated that common germline variants in genes involved in the DNA repair pathway influence breast cancer risk. To assess whether alterations in DNA repair genes contribute to breast cancer, we genotyped 12 single nucleotide polymorphisms (SNPs) in 1,109 Cypriot women with breast cancer and 1,177 age-matched healthy controls. We found significant associations with breast cancer for SNPs in the BRCA2 and MRE11A genes. Carriers of the BRCA2 rs1799944 variant (991 Asp) were found to have an increased risk of breast cancer (OR = 1.41, 95% CI 1.08–1.83, P = 0.01) with P _trend = 0.0076. Homozygous carriers of the MRE11A rs601341 A allele had an increased risk of breast cancer (OR = 1.36, 95% CI 1.08–1.71, P = 0.009) with P _trend = 0.0087. This study suggests that genetic variants in BRCA2 and MRE11A are associated with breast cancer risk.

Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRef

Hamosh A, Scott AF, Amberger JS et al (2005) Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 33(Database issue):D514–D517. doi:10.1093/nar/gki033 PubMedCrossRef

Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11(2):103–105. doi:10.1016/j.ccr.2007.01.010 PubMedCrossRef

Bau DT, Mau YC, Ding SL et al (2007) DNA double-strand break repair capacity and risk of breast cancer. Carcinogenesis 28(8):1726–1730. doi:10.1093/carcin/bgm109 PubMedCrossRef

Kennedy DO, Agrawal M, Shen J et al (2005) DNA repair capacity of lymphoblastoid cell lines from sisters discordant for breast cancer. J Natl Cancer Inst 97(2):127–132PubMed

Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ et al (2007) Genetic susceptibility for breast cancer: How many more genes to be found? Crit Rev Oncol Hematol 63(2):125–149. doi:10.1016/j.critrevonc.2006.12.004 PubMedCrossRef

Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11(12):1513–1530PubMed

Kuschel B, Auranen A, McBride S et al (2002) Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 11(12):1399–1407. doi:10.1093/hmg/11.12.1399 PubMedCrossRef

García-Closas M, Egan KM, Newcomb PA et al (2006) Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 119(4):376–388. doi:10.1007/s00439-006-0135-z PubMedCrossRef

10.

Haiman CA, Hsu C, de Bakker PI et al (2008) Comprehensive association testing of common genetic variation in DNA repair pathway genes in relationship with breast cancer risk in multiple populations. Hum Mol Genet 17(6):825–834. doi:10.1093/hmg/ddm354 PubMedCrossRef

11.

Loizidou MA, Michael T, Neuhausen SL, Newbold RF, Marcou Y, Kakouri E et al (2008) Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus. Breast Cancer Res Treat. Epub ahead of print. doi:10.1007/s10549-007-9881-4

12.

International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437(7063):1299–1320. doi:10.1038/nature04226 CrossRef

13.

Pharoah PDP, Antoniou A, Bobrow M et al (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31:33–36. doi:10.1038/ng853 PubMedCrossRef

14.

Mohrenweiser HW, Jones IM (1998) Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutat Res 400:15–24. doi:10.1016/S0027-5107(98)00059-1 PubMed

15.

Rapakko K, Heikkinen K, Karppinen SM et al (2006) Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families. Cancer Lett 236(1):142–147. doi:10.1016/j.canlet.2005.05.032 PubMedCrossRef

16.

Breast Cancer Information Core Database (BIC) http://research.nhgri.nih.gov/bic/

17.

Fackenthal JD, Sveen L, Gao Q et al (2005) Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients. J Med Genet 42(3):276–281. doi:10.1136/jmg.2004.020446 PubMedCrossRef

18.

Debniak T, Scott RJ, Górski B et al (2008) Common variants of DNA repair genes and malignant melanoma. Eur J Cancer 44(1):110–114. doi:10.1016/j.ejca.2007.10.006 PubMedCrossRef

19.

Freedman ML, Penney KL, Stram DO et al (2004) Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort. Hum Mol Genet 13(20):2431–2441. doi:10.1093/hmg/ddh270 PubMedCrossRef

20.

Hadjisavvas A, Charalambous E, Adamou A et al (2004) Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation. Cancer Genet Cytogenet 151(2):152–156. doi:10.1016/j.cancergencyto.2003.09.020 PubMedCrossRef

21.

Loizidou M, Marcou Y, Anastasiadou V et al (2007) Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus. Clin Genet 71(2):165–170. doi:10.1111/j.1399-0004.2007.00747.x PubMedCrossRef

22.

van den Bosch M, Bree RT, Lowndes NF et al (2003) The MRN complex: coordinating and mediating the response to broken chromosomes. EMBO Rep 4(9):844–849. doi:10.1038/sj.embor.embor925 PubMedCrossRef

23.

Rollinson S, Kesby H, Morgan GJ (2006) Haplotypic variation in MRE11, RAD50 and NBS1 and risk of non-Hodgkin’s lymphoma. Leuk Lymphoma 47(12):2567–2583. doi:10.1080/10428190600909743 PubMedCrossRef

24.

Breast Cancer Association Consortium (2006) Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 98(19):1382–1396CrossRef

Title: DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus
Authors: Maria A. Loizidou
Thalia Michael
Susan L. Neuhausen
Robert F. Newbold
Yiola Marcou
Eleni Kakouri
Maria Daniel
Panayiotis Papadopoulos
Simos Malas
Andreas Hadjisavvas
Kyriacos Kyriacou
Publication date: 01-06-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0084-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Autoimmune hypothyroidism and breast cancer in the elderly

Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months

Vitamin D receptor variants and breast cancer risk in the Polish population

Use of antioxidant supplements during breast cancer treatment: a comprehensive review

Acupuncture for treating hot flashes in breast cancer patients: a systematic review

Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer